Protoporphyrin IX Fluorescence and Photobleaching During Interstitial Photodynamic Therapy of Malignant Gliomas for Early Treatment Prognosis

2013 ◽  
Vol 45 (4) ◽  
pp. 225-234 ◽  
Author(s):  
Ann Johansson ◽  
Florian Faber ◽  
Gesa Kniebühler ◽  
Herbert Stepp ◽  
Ronald Sroka ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Early Treatment ◽  
Malignant Gliomas ◽  
Protoporphyrin Ix ◽  
Interstitial Photodynamic Therapy ◽  
Treatment Prognosis

Protoporphyrin IX kinetics for interstitial photodynamic therapy dosimetry of malignant glioma

2011 ◽  
Vol 8 (2) ◽  
pp. 210-211
Author(s):  
W. Beyer ◽  
A. Johansson ◽  
F. Faber ◽  
G. Palte ◽  
H. Stepp ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Malignant Glioma ◽  
Protoporphyrin Ix ◽  
Interstitial Photodynamic Therapy

scholarly journals Interstitial Photodynamic Therapy Using 5-ALA for Malignant Glioma Recurrences

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1767
Author(s):  
Stefanie Lietke ◽  
Michael Schmutzer ◽  
Christoph Schwartz ◽  
Jonathan Weller ◽  
Sebastian Siller ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Prognostic Factors ◽  
Malignant Glioma ◽  
Treatment Response ◽  
Aminolevulinic Acid ◽  
Malignant Gliomas ◽  
Target Volume ◽  
Risk Profile ◽  
Who Grade ◽  
Interstitial Photodynamic Therapy

Interstitial photodynamic therapy (iPDT) using 5-aminolevulinic acid (5-ALA)-induced protoporphyrin IX (PpIX) as a cytotoxic photosensitizer could be a feasible treatment option for malignant gliomas. In a monocentric cohort of consecutive patients treated between 2006 and 2018, a risk profile analysis of salvage iPDT for local malignant glioma recurrences and associated outcome measures are presented here. It was considered indicated in patients with circumscribed biopsy-proven malignant glioma recurrences after standard therapy, if not deemed eligible for safe complete resection. A 3D treatment-planning software was used to determine the number and suitable positions of the cylindrical diffusing fibers placed stereotactically to ensure optimal interstitial irradiation of the target volume. Outcome measurements included the risk profile of the procedure, estimated time-to-treatment-failure (TTF), post-recurrence survival (PRS) and prognostic factors. Forty-seven patients were treated, of which 44 (median age, 49.4 years, range, 33.4–87.0 years, 27 males) could be retrospectively evaluated. Recurrent gliomas included 37 glioblastomas (WHO grade IV) and 7 anaplastic astrocytomas (WHO grade III). Thirty (68.2%) tumors were O-6-methylguanine-DNA methyltransferase (MGMT)-methylated, 29 (65.9%)—isocitrate dehydrogenase (IDH)-wildtype. Twenty-six (59.1%) patients were treated for their first, 9 (20.5%)—for their second, 9 (20.5%)—for the third or further recurrence. The median iPDT target volume was 3.34 cm3 (range, 0.50–22.8 cm3). Severe neurologic deterioration lasted for more than six weeks in one patient only. The median TTF was 7.1 (95% confidence interval (CI), 4.4–9.8) months and the median PRS was 13.0 (95% CI, 9.2–16.8) months. The 2- and 5-year PRS rates were 25.0% and 4.5%, respectively. The treatment response was heterogeneous and not significantly associated with patient characteristics, treatment-related factors or molecular markers. The promising outcome and acceptable risk profile deserve further prospective evaluation particularly to identify mechanisms and prognostic factors of favorable treatment response.

scholarly journals Liposomal Lapatinib in Combination with Low-Dose Photodynamic Therapy for the Treatment of Glioma

2019 ◽  
Vol 8 (12) ◽  
pp. 2214 ◽  
Author(s):  
Carl Fisher ◽  
Girgis Obaid ◽  
Carolyn Niu ◽  
Warren Foltz ◽  
Alyssa Goldstein ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Cell Lines ◽  
Malignant Gliomas ◽  
Protoporphyrin Ix ◽  
Growth Factor Receptor ◽  
In Vivo Studies ◽  
Epidermal Growth

Background: Malignant gliomas are highly invasive and extremely difficult to treat tumours with poor prognosis and outcomes. Photodynamic therapy (PDT), mediated by Gleolan®, has been studied previously with partial success in treating these tumours and extending lifetime. We aim to determine whether combining PDT using ALA-protoporphyrin IX (PpIX) with a liposomal formulation of the clinical epidermal growth factor receptor (EGFR) inhibitor, lapatinib, would increase the anti-tumour PDT efficacy. Methods: Lapatinib was given in vitro and in vivo 24 h prior to PDT and for 3–5 days following PDT to elicit whether the combination provided any benefits to PDT therapy. Live-cell imaging, in vitro PDT, and in vivo studies were performed to elucidate the effect lapatinib had on PDT for a variety of glioma cell lines and as well as GSC-30 neurospheres in vivo. Results: PDT combined with lapatinib led to a significant increase in PpIX accumulation, and reductions in the LD50 of PpIX mediated PDT in two EGFR-driven cell lines, U87 and U87vIII, tested (p < 0.05). PDT + lapatinib elicited stronger MRI-quantified glioma responses following PDT for two human glioma-derived tumours (U87 and GSC-30) in vivo (p < 0.05). Furthermore, PDT leads to enhanced survival in rats following treatment with lapatinib compared to lapatinib alone and PDT alone (p < 0.05). Conclusions: As lapatinib is approved for other oncological indications, a realization of its potential combination with PDT and in fluorescence-guided resection could be readily tested clinically. Furthermore, as its use would only be in acute settings, long-term resistance should not pose an issue as compared to its use as monotherapy.

Individualization of interstitial photodynamic therapy for malignant gliomas

2019 ◽  
Author(s):  
Maximilian Aumiller ◽  
Adrian Rühm ◽  
Maximilian Eisel ◽  
Christian Freymüller ◽  
Herbert Stepp ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Malignant Gliomas ◽  
Interstitial Photodynamic Therapy

Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX

2007 ◽  
Vol 39 (5) ◽  
pp. 386-393 ◽  
Author(s):  
Tobias J. Beck ◽  
Friedrich W. Kreth ◽  
Wolfgang Beyer ◽  
Jan H. Mehrkens ◽  
Andreas Obermeier ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Malignant Glioma ◽  
Aminolevulinic Acid ◽  
Protoporphyrin Ix ◽  
Interstitial Photodynamic Therapy

Protoporphyrin IX Fluorescence Photobleaching and the Response of Rat Barrett's Esophagus Following 5-aminolevulinic Acid Photodynamic Therapy

2006 ◽  
Vol 82 (6) ◽  
pp. 1638 ◽  
Author(s):  
Ingrid A. Boere ◽  
Dominic J. Robinson ◽  
Henriette S. de Bruijn ◽  
Jolanda Kluin ◽  
Hugo W. Tilanus ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Aminolevulinic Acid ◽  
Protoporphyrin Ix

scholarly journals Systematic Review and Meta-Analysis of In Vitro Anti-Human Cancer Experiments Investigating the Use of 5-Aminolevulinic Acid (5-ALA) for Photodynamic Therapy

2021 ◽  
Vol 14 (3) ◽  
pp. 229
Author(s):  
Yo Shinoda ◽  
Daitetsu Kato ◽  
Ryosuke Ando ◽  
Hikaru Endo ◽  
Tsutomu Takahashi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Photodynamic Therapy ◽  
Aminolevulinic Acid ◽  
Human Cancer ◽  
Meta Analysis ◽  
Protoporphyrin Ix ◽  
Cell Types ◽  
Amino Acid Derivative ◽  
Photodynamic Diagnosis

5-Aminolevulinic acid (5-ALA) is an amino acid derivative and a precursor of protoporphyrin IX (PpIX). The photophysical feature of PpIX is clinically used in photodynamic diagnosis (PDD) and photodynamic therapy (PDT). These clinical applications are potentially based on in vitro cell culture experiments. Thus, conducting a systematic review and meta-analysis of in vitro 5-ALA PDT experiments is meaningful and may provide opportunities to consider future perspectives in this field. We conducted a systematic literature search in PubMed to summarize the in vitro 5-ALA PDT experiments and calculated the effectiveness of 5-ALA PDT for several cancer cell types. In total, 412 articles were identified, and 77 were extracted based on our inclusion criteria. The calculated effectiveness of 5-ALA PDT was statistically analyzed, which revealed a tendency of cancer-classification-dependent sensitivity to 5-ALA PDT, and stomach cancer was significantly more sensitive to 5-ALA PDT compared with cancers of different origins. Based on our analysis, we suggest a standardized in vitro experimental protocol for 5-ALA PDT.

Sign in / Sign up

Export Citation Format

Share Document